申请人:MERZ PHARMA GMBH & CO KGAA
公开号:WO2014180556A1
公开(公告)日:2014-11-13
The present invention relates to arylpiperazines, and to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients, or with anxiety, the instant treatments comprising administering to the individual an effective amount of an arylpiperazine or a pharmaceutically acceptable salt thereof.
本发明涉及芳基哌嗪,以及高效治疗因长期使用L-DOPA治疗帕金森病患者而引起的L-DOPA诱导的舞蹈病,或治疗焦虑症的个体,所述治疗方法包括向个体施用有效量的芳基哌嗪或其药用可接受的盐。